Consumer drug advertising is favorite culprit in rising Rx costs

Share this article:

Consumer drug advertising remains corporate benefit managers' favorite culprit in rising prescription drug costs, according to an Arxcel survey. Forty-five percent cited DTC as the top cause of rising costs, compared to 36% in 2006 and 30% in 2005. R&D costs placed second, with 24%, and an aging population ranked third, at 17%. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?